

Substitute for form 1449/PTO

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Application Number

Filing Date

09/30/2005

First Named Inventor

RUSSWURM	
----------	--

Art Unit

Examiner Name

Attorney Docket Number	9740-1
------------------------	--------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
		WO 1999/40434	08/12/1999	INVITROGEN		
		EP 1 270 740 A1	01/02/2003	SIRS-LAB GMBH		
		WO 2003/002763 A1	01/09/2003	SIRS-LAB GMBH		
		WO 2004/031412 A2	04/15/2004	ONCOTHERAPY SCIENCE		
		WO 2004/06778 A2	08/12/2004	UNIV. OF SOUTH FLORIDA		
		WO 2004/087949 A2	10/14/2004	SIRS-LAB GMBH		


Examiner Signature	/Stephen Kapushoc/	Date Considered	02/09/2009
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

USPTO Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number

Filing Date

09/30/2005

First Named Inventor

RUSSWURM

Art Unit

Examiner Name

Attorney Docket Number

9740-1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHINNAIYAN et al., Molecular Signatures of Sepsis Multiorgan Gene Expression Profiles of Systemic Inflammation, Amer. J. Pathol., 159(4):1199-1209, 10/2001	
		YU et al., Differential gene expression in gram-negative and gram-positive sepsis, Am. J. Respir. Crit. Care Med., 169(10):1135-1143, 05/15/2004	
		SCHLAG et al., The cell in shock: the origin of multiple organ failure, Resuscitation, 21(2-3):137-180, 04/1991	
		PATHAN et al., The complexity of the inflammatory response to meningococcal sepsis revealed by gene expression profiling using cDNA microarrays, Critical Care Med., Bd. 30, Nr. 12, 12/2002	
		WIEGAND et al., Gene Expression Pattern in Human Monocytes as a Surrogate Marker for Systemic Inflammatory Response Syndrome (SIRS), Molecular Med., 5:192-202, 1999	
		PRUCHA et al., Expression Profiling: Toward an Application in Sepsis Diagnostics, Shock, 22(1):29-33, 07/2004	
		COBB et al., Sepsis gene expression profiling: Murine Splenic compared with hepatic responses determined by using complementary DNA microarrays, Crit. Care Med., 30(12):2711-2720, 12/2002	
		DEIGNER, Microarray expression profiling: towards an application in sepsis diagnostics, XP-002327554, www.sirs-lab.de/content/de/pdf/kompetenzen/deigner.pdf, 05/09/2005	
		MIRA et al., Association of TNF2, a TNF- α Promoter Polymorphism, with Septic Shock Susceptibility and Mortality, JAMA, 282(6):561-568, 08/11/1999	
		BARRIERE et al., An overview of mortality risk prediction in sepsis, Crit. Care Med., 23(2):376-393, 1995	

Examiner
Signature

/Stephen Kapushoc/

Date
Considered

02/09/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet

2

of

2

Application Number

Filing Date

09/30/2005

First Named Inventor

RUSSWURM

Art Unit

Examiner Name

Attorney Docket Number

9740-1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BOWTELL, Options Available – From Start to Finish – for Obtaining Expression Data by Microarray, Nature Genetics Supplement, 21:25-32, 01/1999	
		MEMBERS OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS, Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis, Crit. Care Med, 20(6):864-874, 1992	
		HELLER et al., Discovery and Analysis of Inflammatory Disease-Related Genes Using cDNA Microarrays, Proc. Natl. Acad. Sci., 94:2150-2155, 03/1997	
		ROWE et al., An Array Immunosensor for Simultaneous Detection of Clinical Analytes, Anal. Chem., 71:433-439, 1999	
		KOSNY et al., Homo Sapiens (Clone KT2) Bone Morphogenetic Protein-1 (BMP-1) mRNA and Alternatively Spliced Mammalian Tolloid Protein (mTld), XP002307377, European Molecular Biology Laboratory, Database Accession no. L35279, 01/18/1995	
		OBERHOFFER et al., Discriminative power of Inflammatory Markers for Prediction of Tumor Necrosis factor- α and Interleukin-6 in ICU Patients with Systemic Inflammatory Response Syndrome (SIRS) or Sepsis at Arbitrary Time Points, Int. Care Med, 26:S170-S174, 2000	

Examiner
Signature

/Stephen Kapushoc/

Date

Considered

02/09/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/